These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25583779)

  • 21. IDH1/2 Mutations in Cancer Stem Cells and Their Implications for Differentiation Therapy.
    Molenaar RJ; Wilmink JW
    J Histochem Cytochem; 2022 Jan; 70(1):83-97. PubMed ID: 34967233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IDH Inhibitors Target Common Glioma Mutation.
    Cancer Discov; 2019 Aug; 9(8):992. PubMed ID: 31217295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating ivosidenib for the treatment of acute myeloid leukemia.
    Donker ML; Ossenkoppele GJ
    Expert Opin Pharmacother; 2020 Dec; 21(18):2205-2213. PubMed ID: 32808831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
    Dang L; Su SM
    Annu Rev Biochem; 2017 Jun; 86():305-331. PubMed ID: 28375741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
    DiNardo CD; Stein EM
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):769-772. PubMed ID: 30416011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
    Upadhyay VA; Brunner AM; Fathi AT
    Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience.
    Roboz GJ
    Clin Adv Hematol Oncol; 2018 May; 16(5):322-325. PubMed ID: 29851927
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical development of IDH1 inhibitors for cancer therapy.
    Zarei M; Hue JJ; Hajihassani O; Graor HJ; Katayama ES; Loftus AW; Bajor D; Rothermel LD; Vaziri-Gohar A; Winter JM
    Cancer Treat Rev; 2022 Feb; 103():102334. PubMed ID: 34974243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In brief: Two new drugs for AML.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):e56. PubMed ID: 29635267
    [No Abstract]   [Full Text] [Related]  

  • 30. Therapeutic targeting of isocitrate dehydrogenase mutant AML.
    Boddu P; Borthakur G
    Expert Opin Investig Drugs; 2017 May; 26(5):525-530. PubMed ID: 28388242
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
    Heuser M; Palmisiano N; Mantzaris I; Mims A; DiNardo C; Silverman LR; Wang ES; Fiedler W; Baldus C; Schwind S; Pardee T; Perl AE; Cai C; Kaulfuss S; Lagkadinou E; Rentzsch C; Wagner M; Wilkinson G; Wu B; Jeffers M; Genvresse I; Krämer A
    Leukemia; 2020 Nov; 34(11):2903-2913. PubMed ID: 32733012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
    Wang F; Travins J; DeLaBarre B; Penard-Lacronique V; Schalm S; Hansen E; Straley K; Kernytsky A; Liu W; Gliser C; Yang H; Gross S; Artin E; Saada V; Mylonas E; Quivoron C; Popovici-Muller J; Saunders JO; Salituro FG; Yan S; Murray S; Wei W; Gao Y; Dang L; Dorsch M; Agresta S; Schenkein DP; Biller SA; Su SM; de Botton S; Yen KE
    Science; 2013 May; 340(6132):622-6. PubMed ID: 23558173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors.
    Reinbold R; Hvinden IC; Rabe P; Herold RA; Finch A; Wood J; Morgan M; Staudt M; Clifton IJ; Armstrong FA; McCullagh JSO; Redmond J; Bardella C; Abboud MI; Schofield CJ
    Nat Commun; 2022 Aug; 13(1):4785. PubMed ID: 35970853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia.
    Dunn-Valadez S; Bathini S; Elston C; Rangaraju S; Stasi AD; Worth S; Morlote D; Harada S; Vachhani P
    Cancer Treat Res Commun; 2022; 31():100560. PubMed ID: 35460975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enasidenib.
    Krämer A; Bochtler T
    Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells.
    Jones S; Ahmet J; Ayton K; Ball M; Cockerill M; Fairweather E; Hamilton N; Harper P; Hitchin J; Jordan A; Levy C; Lopez R; McKenzie E; Packer M; Plant D; Simpson I; Simpson P; Sinclair I; Somervaille TC; Small H; Spencer GJ; Thomson G; Tonge M; Waddell I; Walsh J; Waszkowycz B; Wigglesworth M; Wiseman DH; Ogilvie D
    J Med Chem; 2016 Dec; 59(24):11120-11137. PubMed ID: 28002956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1.
    Zheng M; Tang R; Deng Y; Yang K; Chen L; Li H
    Bioorg Chem; 2018 Sep; 79():89-97. PubMed ID: 29738972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia.
    Gangat N; McCullough K; Abdelmagid M; Karrar O; Powell M; Al-Kali A; Alkhateeb H; Begna K; Mangaonkar A; Saliba A; Torghabeh MH; Litzow M; Hogan W; Shah M; Patnaik M; Pardanani A; Badar T; Foran J; Palmer J; Sproat L; Yi CA; Tefferi A
    Haematologica; 2024 Jan; 109(1):187-292. PubMed ID: 37534525
    [No Abstract]   [Full Text] [Related]  

  • 39. In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.
    Chaturvedi A; Goparaju R; Gupta C; Weder J; Klünemann T; Araujo Cruz MM; Kloos A; Goerlich K; Schottmann R; Othman B; Struys EA; Bähre H; Grote-Koska D; Brand K; Ganser A; Preller M; Heuser M
    Leukemia; 2020 Feb; 34(2):416-426. PubMed ID: 31586149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of relapsed/refractory AML patients with IDH1
    Largeaud L; Bertoli S; Bérard E; Dufrechou S; Prade N; Gadaud N; Tavitian S; Bories P; Luquet I; Sarry A; Mas V; Huguet F; Delabesse E; Récher C
    Leuk Lymphoma; 2020 Feb; 61(2):473-476. PubMed ID: 31566052
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.